Alphamab Oncology
Alphamab Oncology, a leading biopharmaceutical company headquartered in China, is at the forefront of innovative cancer therapies. Founded in 2016, the company has rapidly established itself in the oncology sector, focusing on the research, development, and commercialisation of monoclonal antibodies and other biologics.
With a strong presence in both domestic and international markets, Alphamab Oncology has achieved significant milestones, including the successful development of its proprietary drug candidates. Their core products, distinguished by their unique mechanisms of action, aim to address unmet medical needs in cancer treatment.
Recognised for its commitment to advancing oncology solutions, Alphamab Oncology continues to strengthen its market position through strategic partnerships and a robust pipeline, making it a notable player in the global biopharmaceutical landscape.
-4 vs industry average
Alphamab Oncology’s score of 34 is higher than 57% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Part of the Sustainability team at Alphamab Oncology?
- Control how your company's emission story is told
- Respond to customers efficiently
- See who's viewing your profile
Industry Intensity
Pharmaceutical Preparation Manufacturing has below-average carbon intensity
Industry performance
The Pharmaceutical Preparation Manufacturing industry has reduced its overall emissions by 19% since 0
Emissions trajectory 2020 – 2028
Reported emissions
Scope 3 accounts for ••• of total emissions.
Alphamab Oncology's reported carbon emissions
In 2025, Alphamab Oncology reported total carbon emissions of approximately 71.9 million kg CO2e. This figure includes Scope 1 emissions of about 8,160 kg CO2e, Scope 2 emissions of approximately 19.3 million kg CO2e, and Scope 3 emissions totalling around 54.8 million kg CO2e, which encompasses categories such as capital goods and purchased goods and services. The company has not set specific reduction targets or initiatives, as indicated by the absence of documented reduction targets or commitments to frameworks like the Science Based Targets initiative (SBTi). This lack of formal climate pledges suggests that Alphamab Oncology is currently focusing on reporting its emissions without established goals for reduction. Overall, while Alphamab Oncology has made strides in transparency regarding its carbon footprint, the absence of reduction commitments highlights an area for potential improvement in its climate strategy.
Unlock detailed emission data
Access structured emission data, company specific factors and auditable source documents
Alphamab Oncology’s Climate Goals (2030 & 2050)
No climate goals have been disclosed for Alphamab Oncology yet.
Scope 3 top emissions categories
4 of 15 categories disclosedSee all scope 3 categories
Already have an account? Sign in now
Emissions comparison with industry peers
View similar organisations
Alphamab Oncology
Usage policy
You’re welcome to quote or reference data from this page, but please include a visible link back to this URL. Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.
Where does DitchCarbondata come from?
Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers
Learn moreCurious to see your top suppliers emissions?
Book a demo for a pilot project